Introduction
============

The discovery of driver mutations has drastically changed clinical practice in patients with lung tumors. The management of lung cancer with appropriate oncoprotein inhibitors is vital for the patient survival ([@B1]). Osimertinib is a third-generation irreversible epidermal-growth-factor-receptor (EGFR)-tyrosine kinase inhibitor (TKI) that has positively changed the standard treatment for non-small-cell lung cancer harboring an EGFR T790M mutation ([@B2]-[@B4]). Therefore, continued treatment with osimertinib is crucial for patients with EGFR-mutant lung cancer.

Unfortunately, some patients discontinue the use of EGFR-TKIs due to toxicities. Drug-induced interstitial lung disease (ILD) is the most common serious adverse event that occurs during EGFR-TKI treatment. Previous clinical trials have reported that osimertinib-induced ILD (OsiILD) occurred in 2-4% of patients ([@B2]-[@B4]). However, only few case reports describing OsiILD have been published, and the specific clinical features are not fully understood. Notably, some cases reported successful re-challenge of patients with osimertinib, even in those with a history of OsiILD.

We herein report a patient who developed OsiILD with an organizing pneumonia (OP) pattern and was re-challenged with osimertinib, along with a literature-based review.

Case Report
===========

A 75-year-old woman with no history of smoking or allergies had postoperative recurrence of lung adenocarcinoma harboring the EGFR exon 19 deletion. She developed cancer-related pleural effusion, which disseminated to the right lung. The patient\'s Eastern Cooperative Group Performance Status (PS) was grade 1, so erlotinib was administered. Three months after the initiation of erlotinib, pleural dissemination and effusion were reduced. ([Fig. 1A, B](#g001){ref-type="fig"}). However, the pleural dissemination and effusion increased one year after beginning the erlotinib treatment.

![The effect of epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI). The black arrow indicates plural dissemination. (A, B) Chest high-resolution computed tomography (HRCT) image three months after the initiation of erlotinib treatment. Right pleural dissemination and effusion were reduced. (C, D) Chest HRCT images three months after the initiation of osimertinib treatment. Right pleural dissemination and effusion were once again reduced.](1349-7235-59-0823-g001){#g001}

Genetic testing of the pleural fluid revealed EGFR exon 19 deletion and an EGFR T790M mutation in cancer cells. The patient\'s PS was maintained at grade 1. Thus, osimertinib was administered, and pleural dissemination to the right lung had almost disappeared by three months after the initiation ([Fig. 1C, D](#g001){ref-type="fig"}); however, the patient complained of cough six months after starting osimertinib administration. Chest high-resolution computed tomography (HRCT) revealed patchy consolidation with a reversed halo sign in the left lower lung lobe ([Fig. 2A, B](#g002){ref-type="fig"}). We suspected that ILD with an OP pattern had been induced by osimertinib; therefore, the anti-cancer drug was immediately discontinued, and she was admitted to our hospital for the diagnosis and treatment. At that time, her oxygen saturation was 98% in room air. Therefore, we considered the lung injury to be mild based on the "Consensus statement for the diagnosis and treatment of drug-induced lung injuries," edited by the Japanese Respiratory Society ([@B5]).

![The clinical course of osimertinib-induced interstitial lung disease with an organizing pneumonia (OP) pattern. (A) Chest HRCT image three months after the initiation of osimertinib treatment. No evidence of lung tumor was detected in the lungs. (B) Chest HRCT image six months after starting osimertinib treatment, showing patchy consolidation (arrow). Some of the consolidation was accompanied by a reversed halo sign (arrowhead). The red arrow indicates a lung lesion on which a lung biopsy was performed. Lung cancer cells were not detected. (C) Chest HRCT image after 46 days of corticosteroid treatment, showing improvement in the abnormal shadow. (D) Chest HRCT image after cytotoxic chemotherapy, indicating increased right plural effusion. (E) Chest HRCT image after four months of osimertinib re-administration, showing decreased right pleural effusion without recurrence of ILD.](1349-7235-59-0823-g002){#g002}

Bronchoscopy was performed on day 2 following hospitalization. We performed a transbronchial lung biopsy from the right posterior segment (S2). The pathological examination did not reveal any specific findings, including the existence of malignant cells or granuloma. The cellular composition of the bronchoalveolar lavage (BAL) fluid was as follows: lymphocytes, 58.5%; eosinophils, 0.5%; neutrophils, 0%; monocytes, 3.0%, and macrophages, 38.0%. The CD4/CD8 ratio was 0.20. Cytology and a polymerase chain reaction test for *Pneumocystis jirovecii* of the BAL fluid were negative. The screening of general bacterial culture and acid-fast *Bacillus* smear and culture were all negative. Blood tests to rule out infections were performed, and the results were follows: procalcitonin \<0.05 ng/mL; (1,3)-beta-D-glucan \<6.0 pg/mL; cryptococcal antigenemia, negative; interferon-gamma release assay (T-SPOT.TB^Ⓡ^), negative; cytomegalovirus viral antigen (pp65.C7-HRP), negative; and anti-mycoplasma pneumoniae IgM antibody, negative. The concentrations of serum Krebs von den Lungen-6 and surfactant protein-D were 1,011 U/mL (reference range, 0-500 U/mL) and 77.3 ng/mL (reference range, 0-110 U/mL), respectively. Therefore, the patient was diagnosed with OsiILD.

As expected, the consolidation shadows gradually improved with 0.6 mg/kg prednisolone (30 mg) ([Fig. 2C](#g002){ref-type="fig"}). Prednisolone was tapered as follows: 30 mg daily for 1 week, 20 mg daily for 1 week, 15 mg daily for 4 weeks, and 10 mg daily for 2 weeks. After that, 5 mg of prednisolone was continued. Fortunately, ILD did not recur during the tapering. After tapering the prednisolone dose, the patient was treated with cytotoxic chemotherapy consisting of carboplatin, paclitaxel, and bevacizumab; however, her treatment was discontinued due to the onset of grade 3 peripheral neuropathy. In addition, right plural effusion gradually increased again during the drug holiday ([Fig. 2D](#g002){ref-type="fig"}). Her Eastern Cooperative Group PS was grade 1.

The patient and her family had a strong will to continue the treatment and provided informed consent to receive re-administration of osimertinib with a maintenance dose of 5 mg prednisolone daily. As a result, the patient has been successfully treated with osimertinib without recurrence of ILD for 7 months ([Fig. 2E](#g002){ref-type="fig"}).

Discussion
==========

We encountered a patient with OsiILD with an OP pattern who was successfully re-administered osimertinib. [Table 1](#t001){ref-type="table"} shows previous case reports of OsiILD ([@B6]-[@B13]). Our literature-based review suggested that ground-glass opacity was the most common HRCT finding, but some cases showed an OP pattern. Our case presented with patchy consolidation with a reversed halo sign, indicating an OP pattern. The frequency of an OP pattern in OsiILD is unclear, and only a few cases of osimertinib-induced ILD with an OP pattern have been reported, although it was reported as a characteristic pattern of first-generation TKI-induced ILD ([@B14]-[@B16]) ([Table 2](#t002){ref-type="table"}).

###### 

Previous Case Reports of Osimertinib-induced ILD in Patients with NSCLC Harboring EGFR T790M.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Case        Age   Sex   *EGFR* status             Smoking pack-year   Onset of ILD   Chest CT pattern               Treatment for ILD   Outcome    Re-challenge\   Corticosteroid during re-challenge   Recurrence of ILD   Effect of osimertinib\
                                                                                                                                                     (mg/body)                                                                (Initial/ Re-challenge)
  ----------- ----- ----- ------------------------- ------------------- -------------- ------------------------------ ------------------- ---------- --------------- ------------------------------------ ------------------- -------------------------
  1 (ref6)    32    M     Exon 19 deletion, T790M   NA                  4.5 months     GGO                            Dexa 10 mg/day      Improved   No \*           Dexa 10 mg/day                       No                  PR/NA

  2 (ref7)    38    F     L858R, T790M              Never               31 days        Diffuse GGO                    Cessation           Improved   Osimertinib\    No                                   Yes                 PR/PR
                                                                                                                                                     (80 mg)                                                                  

  3 (ref8)    75    F     Exon 19 deletion, T790M   Never               64 days        ILST                           PSL 0.5 mg/kg       Improved   Osimertinib\    PSL 0.5 mg/kg\                       No                  PR/PR
                                                                                                                                                     (40 mg)         →tapered 5 mg/day                                        

  4 (ref9)    77    F     L858R, T790M              Never               14 days        Diffuse GGO                    Cessation           Improved   No              NA                                   No                  PR/NA

  5 (ref10)   82    M     Exon 19 deletion, T790M   Never               8 months       Diffuse GGO                    Steroid             Improved   Osimertinib\    PSL 40 mg/day\                       No                  PR/PR
                                                                                                                                                     (80 mg)         →tapered off                                             

  6 (ref10)   60    M     Exon 19 deletion, T790M   NA                  6 weeks        Diffuse GGO                    Steroid             Improved   Osimertinib\    PSL 20 mg/day\                       Yes                 NA/PR
                                                                                                                                                     (NA)            →tapered off                                             

  7 (ref11)   75    M     L858R, T790M              Never               34 days        Diffuse GGO\                   mPSL 500 mg/day     Improved   No              NA                                   No                  NA/NA
                                                                                       Peribronchial consolidation                                                                                                            

  8 (ref12)   59    F     Exon 19 deletion, T790M   NA                  63 days        Patchy GGO and consolidation   Steroid pulse       Improved   No              NA                                   No                  PR/NA

  9 (ref13)   62    M     Exon 19 deletion, T790M   30                  82 days        Multiple GGO                   PSL 0.5 mg/kg       Improved   Osimertinib\    PSL 25 mg/day                        No                  NA/SD
                                                                                                                                                     (40 mg)                                                                  

  10          75    F     Exon 19 deletion, T790M   Never               6 months       OP pattern                     PSL 0.6 mg/kg       Improved   Osimertinib\    PSL 20 mg/day\                       No                  PR/SD
                                                                                                                                                     (80 mg)         →tapered 5mg/day                                         
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

ILD: interstitial lung disease, CT: computed tomography, GGO: ground-glass opacity, ILST: interlobular septal thickening. This patient also suffered pleural effusion

DEXA: dexamethasone, PSL: prednisolone, mPSL: methylprednisolone, NA: not available, PR: partial response, SD: stable disease

^\*^Osimertinib was continued with a dose reduction.

###### 

CT Pattern of First-generation EGFR-TKI-induced ILD.

  Reference   EGFR-TKI    CT pattern                                                    
  ----------- ----------- ------------ ----------- ----------- ------------ ----------- -----
  \(14\)      gefitinib   24 (47.1%)   7 (13.7%)   1 (2.0%)    12 (23.5%)   7 (13.7%)   51
  \(15\)      gefitinib   8 (34.8%)    3 (13.0%)   5 (21.7%)   7 (30.4%)    0           23
  \(16\)      erlotinib   NA           NA          NA          63 (22.3%)   NA          283

EGFR-TKI: epidermal growth factor receptor tyrosine kinase inhibitor, GGO: ground-glass opacity, OP: organizing pneumonia, AEP: acute eosinophilic pneumonia, AIP: acute interstitial pneumonia, NA: not available, ILD: interstitial lung disease, CT: computed tomography

^a^GGO pattern: Only nonspecific area with ground-glass opacity

^b^OP-like pattern: Multifocal areas of airspace consolidation

^c^AEP-like pattern: Patchy distribution of areas with ground-glass opacity accompanied by interlobular septal thickening

^d^AIP-like pattern: Extensive bilateral ground-glass opacity or airspace consolidations with traction bronchiectasis

Interestingly, the re-administration of osimertinib was successful in 83% of cases (5 in 6 cases) in the literature-based review. In general, ILD induced by EGFR-TKIs, such as gefitinib or erlotinib, is severe, and approximately one-third of these cases are fatal ([@B17],[@B18]). Similarly, fatal cases have been reported in clinical trials for osimertinib ([@B4]). At present, there is no consensus regarding the safety and efficacy of re-administering EGFR-TKIs in patients with EGFR-TKI-induced ILD. However, even though the literature shows a high success rate with re-administration of osimertinib, we must be cautious. The high success rate may be due to positive publication bias.

Given that osimertinib has different biological features from other EGFR-TKIs, such as considerably less activity against wild-type EGFR ([@B19]), the disease severity, mortality, and biology of OsiILD might also differ from ILD induced by other EGFR-TKIs. Recently, several groups reported that osimertinib was able to induce transient asymptomatic pulmonary opacities (TAPOs) in 20-35% of patients ([@B20]-[@B22]). The radiological patterns of TAPOs included ground-glass opacity, peribronchial and subpleural nodules, and cryptogenic organizing pneumonia and/or simple eosinophilic pneumonia. According to the reports, these patients with TAPOs were able to be treated with continuous osimertinib therapy or a transient drug holiday followed by osimertinib re-administration ([@B20]-[@B22]). One explanation for the high success rates of osimertinib re-administration noted in our review might be that some patients developed TAPOs rather than OsiILD. At present, there are no definitive ways of confirming whether pulmonary opacities are drug-induced ILD or TAPOs. Further assessments of the radiological patterns and BAL data will be required to investigate this clinical issue.

In conclusion, re-administration of osimertinib for OsiILD might be feasible in select cases. Further studies are required in order to determine the clinical features or specific biomarkers of OsiILD to select which ILD patterns or patients can be treated with or safely re-administered osimertinib.
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